---
title: "Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: References"
description: "Reference list for the formulary evidence report on Tovorafenib (DAY101, TAK-580) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy. 155 cited documents."
canonical: "https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/references"
published: "2026-09-17T18:16:08-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: References

<a id="references"></a>

## 5 References

1. [Alshammari et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13123665/)
2. [Amayiri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10910540/)
3. [Armstrong et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2704230/)
4. [Armstrong et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3064628/)
5. [ASHP AHFS DI Essentials tovorafenib monograph (2025)](https://www.drugs.com/monograph/tovorafenib.html)
6. [Ater et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413276/)
7. [Avery and Hardy (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3947291/)
8. [Bandopadhayay et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4657506/)
9. [Barbato et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10841289/)
10. [Bates et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8860870/)
11. [Bazer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13449833/)
12. [Bennebroek et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12340183/)
13. [Blue Cross Blue Shield Association FEP medical policy 5.21.222 (2025)](https://www.fepblue.org/-/media/PDFs/Medical-Policies/2025/October/Pharmacy-Policies/Remove-and-Replace/521222-Ojemda-tovorafenib.pdf)
14. [Bouffet et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9870224/)
15. [Bouffet et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37733309/)
16. [Brizini et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13320482/)
17. [Buhl et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30530705/)
18. [CDA-AMC dabrafenib plus trametinib reimbursement review (2025)](https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Combined_Review.pdf)
19. [Cherlow et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6548322/)
20. [Chugai Pharmaceutical companion diagnostic announcement (2026)](https://www.chugai-pharm.co.jp/english/news/detail/20260916153000_1280.html)
21. [ClinicalTrials.gov NCT01425008](https://clinicaltrials.gov/study/NCT01425008)
22. [ClinicalTrials.gov NCT03429803](https://clinicaltrials.gov/study/NCT03429803)
23. [ClinicalTrials.gov NCT03871257](https://clinicaltrials.gov/study/NCT03871257)
24. [ClinicalTrials.gov NCT04166409](https://clinicaltrials.gov/study/NCT04166409)
25. [ClinicalTrials.gov NCT05566795](https://clinicaltrials.gov/study/NCT05566795)
26. [CMS advanced diagnostic laboratory tests list (2025)](https://www.cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)
27. [Crotty et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850343/)
28. [DailyMed OJEMDA prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad)
29. [Damodharan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13372930/)
30. [Day One Biopharmaceuticals accelerated approval announcement (2024)](https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated)
31. [Day One Biopharmaceuticals and Servier FIREFLY-2 enrollment announcement (2026)](https://servier.mediaroom.com/2026-05-08-Day-One-and-Servier-Complete-Enrollment-in-Pivotal-Phase-3-FIREFLY-2-Trial-of-Tovorafenib-as-a-Front-Line-Treatment-for-Pediatric-Low-Grade-Glioma-pLGG)
32. [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2025)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_VF.pdf)
33. [Day One Biopharmaceuticals Connecticut prescriber price disclosure (2026)](https://www.dayonebio.com/wp-content/uploads/Ojemda-Connecticut_01.07.26.pdf)
34. [Day One Biopharmaceuticals EveryDay Support HCP support team page](https://www.everydaysupport.com/hcp/your-support-team/)
35. [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)
36. [Day One Biopharmaceuticals fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066926/dawn-ex99_1.htm)
37. [Day One Biopharmaceuticals OJEMDA support page](https://www.ojemda.com/support-from-day-one)
38. [Day One Biopharmaceuticals preliminary 2025 revenue announcement (2026)](https://www.globenewswire.com/news-release/2026/01/11/3216499/0/en/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance.html)
39. [Day One Biopharmaceuticals Schedule 14D-9 (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526125045/d55037dsc14d9.htm)
40. [Day One Biopharmaceuticals Series A announcement (2020)](https://ir.dayonebio.com/news-releases/news-release-details/day-one-biopharmaceuticals-shares-plans-rapidly-develop-new)
41. [de Blank et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4764436/)
42. [de Blank et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7410089/)
43. [de Bont and Schouten-van Meeteren (2024)](https://pubmed.ncbi.nlm.nih.gov/39400717/)
44. [Dodgshun et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26207610/)
45. [EMA Ojemda medicine overview (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda)
46. [EMA Ojemda product information (2026)](https://www.ema.europa.eu/en/documents/product-information/ojemda-epar-product-information_en.pdf)
47. [EMA Ojemda public assessment report (2026)](https://www.ema.europa.eu/en/documents/assessment-report/ojemda-epar-public-assessment-report_en.pdf)
48. [Embring et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12926702/)
49. [Erker et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11276207/)
50. [Falzon et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29343527/)
51. [Fangusaro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6628202/)
52. [Fangusaro et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8485450/)
53. [Fangusaro et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10768984/)
54. [Fangusaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12526141/)
55. [Farias de Alvarenga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12969682/)
56. [FDA accelerated approval announcement (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric)
57. [FDA approval letter NDA 217700 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217700Orig1s000ltr.pdf)
58. [FDA multi-discipline review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000MultidisciplineR.pdf)
59. [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)
60. [FDA risk assessment and risk mitigation review NDA 217700 and 218033 (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217700Orig1s000,%20218033Orig1s000RiskR.pdf)
61. [FDA supplement approval letter NDA 217700 (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217700Orig1s002,%20s003,%20s004ltr.pdf)
62. [Figueira and Pigott (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13499688/)
63. [Fisher et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3367846/)
64. [Forbrigger et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13569998/)
65. [Foundation Medicine (2025)](https://www.foundationmedicine.com/press-release/fda-approval-foundationone-cdx-ojemda)
66. [G-BA benefit assessment procedure tovorafenib (2026)](https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1342/)
67. [G-BA Nutzenbewertung tovorafenib (2026)](https://www.g-ba.de/downloads/92-975-9845/2026-08-17_Nutzenbewertung-G-BA_Tovorafenib_D-1319.pdf)
68. [Gajjar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40073837/)
69. [Gascon et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2055)
70. [Gascon et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41740060/)
71. [Giantini-Larsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40355786/)
72. [Gnekow et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3452343/)
73. [Gnekow et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5517338/)
74. [Gnekow et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31108561/)
75. [Grin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42414678/)
76. [Hammad et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38754050/)
77. [Hanania et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33739455/)
78. [Hargrave et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13161904/)
79. [HAS OJEMDA early access decision (2026)](https://www.has-sante.fr/jcms/p_4214248/fr/ojemda-tovorafenib-gliome-de-bas-grade-pediatrique)
80. [HTACG tovorafenib JCA report (2026)](https://health.ec.europa.eu/document/download/395c2ba0-849a-4f3b-9251-aa2495b3efd7_en?filename=HTA_20260507_TEST_JCA_report_Ojemda_en.pdf)
81. [HTACG tovorafenib JCA summary report (2026)](https://health.ec.europa.eu/document/download/1aa5dab6-6c43-4692-91b9-c50e96a6679a_en?filename=hta_jca_mp_202406_tovorafenib_summary-report_en.pdf)
82. [ICER Launch Price and Access Report (2025)](https://icer.org/wp-content/uploads/2025/10/ICER_2025_Launch-Price-and-Access-Final-Report_For-Publication.pdf)
83. [Ipsen and Day One Biopharmaceuticals licensing announcement (2024)](https://www.ipsen.com/press-release/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovorafenib-for-the-most-common-childhood-brain-tumor-2918482/)
84. [Ipsen EU approval announcement (2026)](https://www.ipsen.com/press-release/ojemda-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-3278647/)
85. [Ipsen H1 2026 results (2026)](https://www.ipsen.com/wp-content/uploads/2026/07/Ipsen-PR_HY-2026_30072026.pdf)
86. [IPSEN Japan approval announcement (2026)](https://bio.nikkeibp.co.jp/atcl/release/26/09/17/28792/)
87. [Ipsen Joint Clinical Assessment publication update (2026)](https://www.ipsen.com/update/ipsen-welcomes-the-european-unions-publication-of-the-joint-clinical-assessment-for-ojemda-tovorafenib-3309159/)
88. [IQWiG dossier assessment G26-11 (2026)](https://www.g-ba.de/downloads/92-975-9846/2026-08-17_Bewertung-Therapiekosten-Patientenzahlen-IQWiG_Tovorafenib_D-1319.pdf)
89. [IQWiG G26-11 project page (2026)](https://www.iqwig.de/en/projects/g26-11.html)
90. [Jacob et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21610151/)
91. [Jalal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832571/)
92. [Jones et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2577184/)
93. [Jones et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3951336/)
94. [Kelada et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32333636/)
95. [Khuong Quang et al. (2026)](https://asn.currinda2.com/website/events/6/days/2026-07-01/abstract/832)
96. [Kilburn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10803270/)
97. [Kline et al. (2024a)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10036)
98. [Kline et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11183845/)
99. [Kline et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10029)
100. [Kline et al. (2026a)](https://academic.oup.com/neuro-onc-peds/article/2/2/wuag022/8661078)
101. [Kline et al. (2026b)](https://asn.currinda2.com/website/events/6/days/2026-07-01/abstract/755)
102. [Krishnatry et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26970559/)
103. [Lafay-Cousin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18098210/)
104. [Lassaletta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573663/)
105. [Lassaletta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5791837/)
106. [Lassaletta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819670/)
107. [Louis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/)
108. [Merchant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799064/)
109. [Miser et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10020904/)
110. [Musial-Bright et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21538130/)
111. [NCCN Guidelines Pediatric Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509)
112. [NICE ID6557 project information (2025)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11693)
113. [NICE TA977 (2024)](https://www.nice.org.uk/guidance/ta977/resources/dabrafenib-with-trametinib-for-treating-braf-v600e-mutationpositive-glioma-in-children-and-young-people-aged-1-year-and-over-pdf-82615854973381)
114. [Nobre et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446502/)
115. [Nwachukwu et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4323958/)
116. [Nysom et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12187376/)
117. [O'Hare et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11300023/)
118. [Peipert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11552847/)
119. [Perreault et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6935133/)
120. [Pharma Japan (2026)](https://pj.jiho.jp/article/256174)
121. [Picariello et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13268981/)
122. [Price et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448625/)
123. [Raabe et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086658/)
124. [Rafia et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41825798/)
125. [Ramagopalan and Pannelay (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13329894/)
126. [Rasco et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10261210/)
127. [Rios et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8722113/)
128. [Rocque et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6944277/)
129. [Roka et al. (2024)](https://doi.org/10.1016/j.ejcped.2024.100169)
130. [Roser et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30970149/)
131. [Ruggiero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12939502/)
132. [Ryall et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066826/)
133. [Ryall et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7169997/)
134. [Servier (2026)](https://servier.com/wp-content/uploads/2026/04/Press-Release_Servier-DayOne_Closing_23.04.2026.pdf)
135. [Servier acquisition completion announcement (2026)](https://servier.com/en/newsroom/servier-completes-the-acquisition-of-day-one-biopharmaceuticals/)
136. [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11996598/)
137. [SIOPE Brain Tumour Group standard clinical practice recommendations (2022)](https://siope.eu/media/documents/escp-low-grade-gliomas-lgg.pdf)
138. [Stiller et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6371471/)
139. [Stokland et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3018938/)
140. [Sturm et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10115638/)
141. [Styczewska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13168116/)
142. [Sun et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5464455/)
143. [Tkacik et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10149214/)
144. [Tsang et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29280458/)
145. [Tsimicalis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21370401/)
146. [van Tilburg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10826080/)
147. [Warner et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4295420/)
148. [Wen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34838156/)
149. [Williams et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/26808258/)
150. [Wilne et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17644483/)
151. [Witt et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.10037)
152. [Wright et al. (2026)](https://ascopubs.org/doi/10.1200/OA-26-00010)
153. [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12988086/)
154. [Zelt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398936/)
155. [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12927753/)

## Related pages
- [Tovorafenib (DAY101): RAF-altered pediatric low-grade glioma requiring first-line systemic therapy](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Terms and abbreviations](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/terms-and-abbreviations.md)
- [Tovorafenib (DAY101): RAF-altered pediatric low-grade glioma requiring first-line systemic therapy](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/executive-summary.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Product information and disease description](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/product-information-and-disease-description.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Clinical evidence](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/clinical-evidence.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Economic information and modeling report](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/economics) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/economics.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: prevalence by geography](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/prevalence) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/prevalence.md)
- [Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/cost-effectiveness-analyses.md)
